Accretion Pharmaceuticals share price
NSE: ACCPLPharmaceuticals & Biotechnology
Last close ₹182.10down ₹7.20 (3.80%)
Share price at the NSE close on 23 Oct 2026. Previous close ₹189.30.
52-week range of traded prices to 23 Oct 2026
₹54.60Low, 27 Oct 2025₹220.00High, 30 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price.
- ₹202 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 8 May 2026
- 20.9
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 8 May 2026
- 3.7
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 8 May 2026
- 27.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 8 May 2026
- 0.23
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 7,200100.0% delivered
Results
Standalone; ₹ crore, the charts by years to March, the table by half year.Half-yearly results
Half year to Mar 2026, against the half year beforeFiled 8 May
- RevenueRevenue. The pill is the change in revenue against the half year before: this period's figure divided by that one's, less one, in per cent.
- ₹46 Crup 4.93%
- Net profitNet profit. The pill is the change in net profit against the half year before: this period's figure divided by that one's, less one, in per cent.
- ₹4.92 Crup 3.43%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 10.7%
Revenue by year
Peak revenue ₹90 Cr, year to Mar 2026
Net profit by year, a loss in red
| ₹ crore | Sep 2024Filed 11 Jun | Mar 2025Filed 11 Jun | Sep 2025Filed 14 Nov | Mar 2026Filed 8 May |
|---|---|---|---|---|
| Revenue | 18.6 | 38.8 | 43.7 | 45.9 |
| Net profit | 2.5 | 4.3 | 4.8 | 4.9 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 13.3% | 11.2% | 10.9% | 10.7% |
Standalone. The 4 half years from Sep 2024, the first on record. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceutical, which carries all its revenue.
Valuation
Today, against the company's own history. Not shown, EV/EBITDA: a period of the last twelve months does not state its operating profit. Dividend yield is not shown: no dividend in the years on record.PE ratio and valuation history
Price to earningsPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
At or below today's level on 81% of 238 trading days over the last year.
LowestHighest
Its median12.0Industry median28.3
Price to bookPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
At or below today's level on 80% of 223 trading days since Nov 2025.
LowestHighest
Its median2.4Industry median2.8
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Accretion Pharmaceuticals in market cap.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 BDH IndustriesBDH | 244 | 20.8 | 3.2 | 14.2 | +44.8% | +22.9% | 16.1% | 18.2% | 1.18% |
 Everest OrganicsEVERESTO | 222 | 42.2 | 2.9 | 13.8 | +5.5% | −15.2% | 7.2% | 10.5% | 0.00% |
 Gennex LaboratoriesGENNEX | 211 | 11.5 | 0.9 | 9.1 | +24.1% | +7.3% | 9.0% | 7.0% | 0.00% |
 Sat Kartar LifeSATKARTAR | 206 | 12.0 | 3.0 | – | – | – | 28.7% | – | 0.54% |
 Nectar LifesciencesNECLIFE | 200 | – | 0.3 | – | −99.7% | – | −31.9% | −15.4% | 0.00% |
 Accretion NutravedaANL | 198 | 39.0 | 5.6 | – | – | – | 14.3% | – | 0.00% |
| Bio Medica LaboratoriesBMLL | 188 | 16.1 | – | – | – | – | 44.2% | – | 0.00% |
 Sanjivani ParanteralSANJIVIN | 188 | – | 3.9 | 13.5 | +13.2% | – | – | 20.2% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
10 Oct · Amendment to AOA/MOA
10 Oct · Meeting
10 Oct · Meeting
Sep 2026
9 Sep · Meeting
1 Sep · Amendment to AOA/MOA
Accretion Pharmaceuticals share price by year
Each calendar year to 2025.Accretion Pharmaceuticals share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 87.85 | – | 101.05 | 54.60 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2025 is from its first session, 21 May 2025.
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 189.20 | 190.00 | 182.10 | 182.10 | 188.43 | 7,200 | 100.0% |
| 22 Oct 2026 | 183.30 | 190.00 | 183.30 | 189.30 | 186.43 | 9,600 | 87.5% |
| 21 Oct 2026 | 183.65 | 192.85 | 183.60 | 192.85 | 186.03 | 4,800 | 75.0% |
| 13 Oct 2026 | 198.90 | 198.90 | 193.20 | 193.20 | 196.01 | 4,800 | 100.0% |
| 12 Oct 2026 | 190.00 | 190.00 | 190.00 | 190.00 | 190.00 | 1,200 | 100.0% |
| 9 Oct 2026 | 187.85 | 189.00 | 180.00 | 188.95 | 188.39 | 48,000 | 90.0% |
| 8 Oct 2026 | 184.05 | 185.90 | 178.50 | 180.00 | 182.69 | 27,600 | – |
| 7 Oct 2026 | 186.00 | 186.00 | 184.30 | 185.30 | 184.64 | 42,000 | 88.6% |
| 6 Oct 2026 | 190.80 | 194.00 | 184.40 | 193.95 | 190.24 | 16,800 | 100.0% |
| 5 Oct 2026 | 195.05 | 195.05 | 193.15 | 194.05 | 193.43 | 34,800 | 93.1% |
Prices in ₹ per share as traded, not adjusted.
Company details
- Legal name
- Accretion Pharmaceuticals Limited
- NSE symbol
- ACCPL
- ISIN
- INE0T8T01010
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- May 2025
- Face value
- ₹10